MEMANTINE AUGMENTATION IN THE TREATMENT OF FRONTAL LOBE SYNDROME IN PATIENTS WITH END-STAGE RENAL DISEASE: A CASE REPORT
Aida Abdul Razak, T Maniam*, Hatta Sidi, Shalisah Sharip, Suriati Mohamed Saini
Objective: This case report highlights the challenges in managing Frontal Lobe Syndrome (FLS) in a patient with end-stage renal disease. Methods: This is a case description of a 58-year-old gentleman who presented with behavioral changes: irritability, mood lability, aggression, psychosis, and overfamiliarity. His presenting symptoms were in keeping with (FLS) with positive findings on Computed Tomography (CT) scan of the brain and also neuropsychological assessments. Difficulties arose in attempts to control his aggression without further compromising his renal function. Results: The usage of the commonly used antipsychotics in controlling aggression was restricted in view of the patient’s renal impairment. Augmentation with low dose memantine proved to be beneficial in this case, without causing further deterioration in renal function. Conclusion: The use of memantine to augment the effect of risperidone was observed to be safe and successful in managing the behavioral changes associated with FLS in adults with end-stage renal disease.